Gastroretentive Drug Delivery Systems Outsourcing Global Market Report 2024

The gastroretentive drug delivery systems outsourcing market size has grown strongly in recent years. It will grow from $1.29 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to the rising drug delivery systems, rising prevalence of gastric cancer, rising incidence of stomach and small intestine disorders, rise in government initiatives, and increase in the number of hospitals.

The gastroretentive drug delivery systems outsourcing market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2028 at a compound annual growth rate (CAGR) of 8%. The projected expansion during the forecast period can be credited to the rise in ambulatory centers, the emphasis on enhancing patient compliance and convenience, the surge in chronic diseases, the growth of personalized medicine, and the increasing elderly population. Key trends expected in the forecast period involve progressions in polymer science, formulation technologies, bioadhesive systems, novel polymers, drug release modifiers, the innovation of gastroretentive dosage forms, the incorporation of digital health technologies, smart gastroretentive systems, and targeted drug delivery.

The anticipated increase in gastrointestinal disorders is set to drive the expansion of the gastroretentive drug delivery systems outsourcing market in the foreseeable future. Gastrointestinal disorders encompass a broad spectrum of conditions affecting various parts of the digestive system, including the stomach, liver, gallbladder, intestines, and pancreas. Factors contributing to the rise in gastrointestinal disorders include aging demographics, the use of antibiotics, exposure to infectious agents, dietary shifts, stress, lifestyle changes, and obesity. Outsourcing the development of gastroretentive drug delivery systems equips pharmaceutical firms with the necessary resources and specialized knowledge to confront the escalating challenge of gastrointestinal disorders, ultimately enhancing patient outcomes and quality of life. For example, the International Foundation for Gastrointestinal Disorders (IFFGD), a nonprofit organization dedicated to education and research, estimates that Irritable Bowel Syndrome (IBS), a prevalent functional gastrointestinal disorder, affects 5-10% of the global population and 25-45 million individuals in the United States alone. IBS alone accounts for 20-40% of gastroenterologist visits, underscoring its substantial impact on individuals and healthcare resources. Hence, the increasing prevalence of gastrointestinal disorders serves as a catalyst for the growth of the gastroretentive drug delivery systems outsourcing market.

Major companies within the gastroretentive drug delivery systems outsourcing market are concentrating on the development of innovative products, such as proton pump inhibitors (PPIs), aimed at improving drug delivery effectiveness and patient convenience. PPIs constitute a category of medications commonly prescribed to address ailments linked to heightened stomach acid levels. For example, in March 2021, Xiromed LLC, a pharmaceutical firm headquartered in the United States, introduced Omeprazole Delayed Release Capsules, 20mg, a generic version of Prilosec. Prilosec (omeprazole) is a proton pump inhibitor utilized in the management of conditions induced by excessive stomach acid production. The formulation of Omeprazole Delayed-Release Capsules provides patients with a consistent and easily identifiable dosage form for omeprazole, thereby facilitating treatment for various gastrointestinal disorders. The distinctive color and coding of the capsules contribute to patient adherence and medication administration accuracy, ensuring optimal dosing and therapeutic effectiveness.

In August 2022, Catalent Inc., a pharmaceutical company headquartered in the United States, completed the acquisition of Metrics Contract Services (Metrics) for an estimated $475 million. Through this strategic move, Catalent intends to fortify its integrated capabilities in oral solid formulation development, manufacturing, and packaging, thereby augmenting its capacity to handle potent compounds and improving its capacity to satisfy customer demands and patient requirements. Metrics Contract Services, based in the United States, is a contract development and manufacturing organization (CDMO) that specializes in providing services for pharmaceutical product development, manufacturing, and analytical testing.

Major companies operating in the gastroretentive drug delivery systems outsourcing market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Evonik Industries AG, Alcon Inc., SGS SA, Lonza Group AG, FMC Corporation, Sun Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup Inc., Cadila Pharmaceuticals, Ashland Global Holdings Inc, Lupin Limited, Torrent Pharmaceuticals Ltd., Evotec SE, Colorcon Inc., Ranbaxy Laboratories Limited, Quotient Sciences Limited, Aenova Group, Vectura Group Ltd., Assertio Therapeutics Inc., Coating Place Inc., Xiromed LLC, SPI Pharma Inc.

North America was the largest region in the gastroretentive drug delivery systems outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroretentive drug delivery systems outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroretentive drug delivery systems outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastroretentive drug delivery systems outsourcing involves pharmaceutical firms engaging external service providers or contract research organizations (CROs) to create and produce drug delivery systems intended to extend the duration of medication within the gastrointestinal (GI) tract. These systems are crafted to boost drug absorption, enhance therapeutic effectiveness, and optimize patient results.

The primary categories of gastroretentive drug delivery systems outsourcing include floating systems, bioadhesive systems, and other variants. A floating drug delivery system (FDDS) is tailored to extend the retention period of medications in the stomach and upper gastrointestinal tract. These systems come in various dosage forms such as tablets, liquids, microspheres, capsules, and others, serving diverse applications such as gastroesophageal reflux disease (GERD), neurological disorders, and more. They are utilized by a range of end-users, including pharmaceutical companies, contract research organizations (CROs), and others.

The gastroretentive drug delivery systems outsourcing market research report is one of a series of new reports that provides gastroretentive drug delivery systems outsourcing market statistics, including gastroretentive drug delivery systems outsourcing industry global market size, regional shares, competitors with a gastroretentive drug delivery systems outsourcing market share, detailed gastroretentive drug delivery systems outsourcing market segments, market trends, and opportunities, and any further data you may need to thrive in the gastroretentive drug delivery systems outsourcing industry. This gastroretentive drug delivery systems outsourcing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastroretentive drug delivery systems outsourcing market consists of revenues earned by entities by providing services such as analytical and testing services, formulation development, quality assurance and control, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroretentive drug delivery systems outsourcing market also includes sales of bioadhesive systems, swelling systems, and high-density systems, and floating systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.